For research use only. Not for therapeutic Use.
4-(2,2,3-Trimethylcyclopentyl)butanoic acid (CAT: I000229) is an orthosteric, insurmountable antagonist of the human bitter taste receptors hTAS2R31 and hTAS2R43. By binding to these receptors, this compound blocks their activation by bitter tastants, thus inhibiting the perception of bitter taste. This property could have potential applications in the development of bitter taste-masking agents for pharmaceuticals or food products, where the bitter taste of certain compounds needs to be masked to improve palatability. Further research is warranted to explore the full potential and applications of this compound in taste modulation.
| Catalog Number | I000229 |
| CAS Number | 957136-80-0 |
| Synonyms | GIV3727 |
| Molecular Formula | C12H22O2 |
| Purity | ≥95% |
| Target | Taste Receptor |
| Storage | -20°C |
| IUPAC Name | 4-(2,2,3-trimethylcyclopentyl)butanoic acid |
| InChI | InChI=1S/C12H22O2/c1-9-7-8-10(12(9,2)3)5-4-6-11(13)14/h9-10H,4-8H2,1-3H3,(H,13,14) |
| InChIKey | LYFXCRCUENNESS-UHFFFAOYSA-N |
| SMILES | CC1CCC(C1(C)C)CCCC(=O)O |
| Reference | <span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”><span style=”box-sizing: border-box; font-variant-ligatures: normal; orphans: 2; widows: 2;”>1. </span><span class=”authors” data-text=”Slack, J.P., Brockhoff, A., Batram, C., et al.” style=”box-sizing: border-box; font-variant-ligatures: normal; orphans: 2; widows: 2;”><span style=”box-sizing: border-box;”><span class=”scientificMarkup” style=”box-sizing: border-box;”>Slack, J.P., Brockhoff, A., Batram, C., <span class=”foreign” style=”box-sizing: border-box; font-style: italic;”>et al</span>.</span></span></span><span class=”title” data-text=”Modulation of bitter taste perception by a small molecule hTAS2R antagonist” style=”box-sizing: border-box; font-variant-ligatures: normal; orphans: 2; widows: 2;”> <span style=”box-sizing: border-box;”><span class=”scientificMarkup” style=”box-sizing: border-box;”>Modulation of bitter taste perception by a small molecule hTAS2R antagonist</span></span>.</span><span class=”journal” style=”box-sizing: border-box; font-style: italic; font-variant-ligatures: normal; orphans: 2; widows: 2;”> Curr. Biol.</span><span class=”number” style=”box-sizing: border-box; font-weight: 700; font-variant-ligatures: normal; orphans: 2; widows: 2;”> </span><span class=”pagerange” style=”box-sizing: border-box; font-variant-ligatures: normal; orphans: 2; widows: 2;”>20 (12), 1104-1109</span><span class=”year” style=”box-sizing: border-box; font-variant-ligatures: normal; orphans: 2; widows: 2;”> (2010)</span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>.</span></span></span> |
